NASDAQ:JAGX Jaguar Health (JAGX) Stock Price, News & Analysis → Your Money is Not Safe (From American Alternative) (Ad) Free JAGX Stock Alerts $0.09 +0.02 (+23.32%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.07▼$0.0950-Day Range$0.06▼$0.1452-Week Range$0.05▼$1.22Volume61.88 million shsAverage Volume79.55 million shsMarket Capitalization$4.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Jaguar Health alerts: Email Address Jaguar Health MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish14.66% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.83) to ($0.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.11 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Jaguar Health. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.66% of the outstanding shares of Jaguar Health have been sold short.Short Interest Ratio / Days to CoverJaguar Health has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Jaguar Health has recently increased by 52.15%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldJaguar Health does not currently pay a dividend.Dividend GrowthJaguar Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for JAGX. Previous Next 2.6 News and Social Media Coverage News SentimentJaguar Health has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Jaguar Health this week, compared to 2 articles on an average week.Search Interest14 people have searched for JAGX on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat Follows24 people have added Jaguar Health to their MarketBeat watchlist in the last 30 days. This is an increase of 85% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jaguar Health insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.16% of the stock of Jaguar Health is held by insiders.Percentage Held by InstitutionsOnly 12.04% of the stock of Jaguar Health is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Jaguar Health are expected to grow in the coming year, from ($5.83) to ($0.40) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyBombshell 2024 election documentary 2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.All the facts are here. About Jaguar Health Stock (NASDAQ:JAGX)Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.Read More JAGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JAGX Stock News HeadlinesMarch 29, 2024 | americanbankingnews.comStockNews.com Initiates Coverage on Jaguar Health (NASDAQ:JAGX)March 21, 2024 | americanbankingnews.comJaguar Health (NASDAQ:JAGX) Coverage Initiated by Analysts at StockNews.comMarch 29, 2024 | Porter & Company (Ad)Bombshell 2024 election documentary 2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.March 20, 2024 | edition.cnn.comJaguar Health, Inc.March 20, 2024 | finance.yahoo.comGEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to MarketMarch 15, 2024 | finance.yahoo.comCapricor Therapeutics, Inc. (4LN2.F)March 1, 2024 | msn.comWhat In The World Is Going On With Jaguar Health (JAGX) Stock?February 23, 2024 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health Requests and Receives Hearing on Nasdaq Listing ComplianceMarch 29, 2024 | Porter & Company (Ad)Bombshell 2024 election documentary 2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.February 17, 2024 | money.usnews.comJaguar Health IncFebruary 15, 2024 | finance.yahoo.comJaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in DogsFebruary 14, 2024 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct ReliefFebruary 14, 2024 | finance.yahoo.comJaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct ReliefFebruary 12, 2024 | ca.finance.yahoo.comJaguar Health, Inc. (JAGX)February 12, 2024 | finance.yahoo.comJaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related DiarrheaJanuary 31, 2024 | investing.comJaguar Health Inc (JAGX)January 30, 2024 | msn.com'Rainforests Are Nature's Medicine Cabinets': Biotech Co. Performs Fresh Research On Traditional Plants For Modern Mental Health ChallengesJanuary 30, 2024 | finance.yahoo.comMagdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical RegionsJanuary 29, 2024 | finance.yahoo.comJaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select ConferenceJanuary 25, 2024 | finance.yahoo.comDog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health’s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)January 22, 2024 | finance.yahoo.comJaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 4, 2024 | finance.yahoo.comIssuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)December 18, 2023 | finance.yahoo.comJaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 61%December 11, 2023 | finance.yahoo.comA Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage IIDecember 8, 2023 | morningstar.comJaguar Health Inc JAGXDecember 7, 2023 | finance.yahoo.comMASCC (Multinational Association of Supportive Care in Cancer) Webinar on GI Toxicities from Cancer Therapies Made Possible by Grant From Napo Pharmaceuticals, a Jaguar Health Family CompanyDecember 6, 2023 | finance.yahoo.comStudy Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) WebsiteSee More Headlines Receive JAGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/17/2021Today3/29/2024Next Earnings (Confirmed)4/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:JAGX CUSIPN/A CIK1585608 Webwww.jaguaranimalhealth.com Phone(415) 371-8300FaxN/AEmployees60Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,450,000.00 Net Margins-370.40% Pretax Margin-380.79% Return on Equity-1,191.67% Return on Assets-79.95% Debt Debt-to-Equity Ratio22.00 Current Ratio1.77 Quick Ratio1.10 Sales & Book Value Annual Sales$11.96 million Price / Sales0.38 Cash FlowN/A Price / Cash FlowN/A Book Value($0.32) per share Price / Book-0.28Miscellaneous Outstanding Shares50,760,000Free Float50,675,000Market Cap$4.56 million OptionableNo Data Beta1.31 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMs. Lisa A. Conte (Age 65)Founder, CEO, President & Director Comp: $771.4kDr. Pravin R. Chaturvedi Ph.D. (Age 61)Chief Scientific Officer & Chair of Scientific Advisory Board Comp: $539.04kMr. Jonathan S. Wolin CPA (Age 61)J.D., M.B.A., Chief of Staff, Chief Compliance Officer & General Counsel Comp: $520.29kMr. Ian H. Wendt M.B.A. (Age 56)Chief Commercial Officer Comp: $441.31kDr. Steven R. King Ph.D. (Age 66)Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary Comp: $477.66kMs. Carol R. Lizak M.B.A. (Age 60)Chief Financial Officer Mr. Peter HodgeSenior Director of Investor Relations, Business Development & Special EventsDr. Karen J. Brunke Ph.D. (Age 71)Executive VP of Corporate & Business Development Mr. David SesinChief Manufacturing OfficerMore ExecutivesKey CompetitorsKintara TherapeuticsNASDAQ:KTRAPhaseBio PharmaceuticalsNASDAQ:PHASAridis PharmaceuticalsNASDAQ:ARDSPetros PharmaceuticalsNASDAQ:PTPIPaxMedicaNASDAQ:PXMDView All Competitors JAGX Stock Analysis - Frequently Asked Questions How have JAGX shares performed in 2024? Jaguar Health's stock was trading at $0.1514 at the beginning of the year. Since then, JAGX shares have decreased by 40.6% and is now trading at $0.0899. View the best growth stocks for 2024 here. When is Jaguar Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024. View our JAGX earnings forecast. How can I listen to Jaguar Health's earnings call? Jaguar Health will be holding an earnings conference call on Monday, April 1st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Jaguar Health's earnings last quarter? Jaguar Health, Inc. (NASDAQ:JAGX) released its quarterly earnings data on Wednesday, November, 17th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.09. The biotechnology company had revenue of $0.63 million for the quarter. Jaguar Health had a negative trailing twelve-month return on equity of 1,191.67% and a negative net margin of 370.40%. During the same period in the prior year, the firm earned ($0.63) EPS. When did Jaguar Health's stock split? Jaguar Health shares reverse split on Wednesday, September 8th 2021. The 1-3 reverse split was announced on Wednesday, September 8th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 8th 2021. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split. What other stocks do shareholders of Jaguar Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), Trevena (TRVN), Vaxart (VXRT), Purple Biotech (KTOV), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Biopharmx (BPMX), Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT). When did Jaguar Health IPO? Jaguar Health (JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers. Who are Jaguar Health's major shareholders? Jaguar Health's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Jaguar Health? Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:JAGX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeYour Money is Not SafeAmerican AlternativeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaThe ONE AI Sock to own now. (It’s not Nvidia.)Weiss Ratings“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jaguar Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.